Methotrexate

News Methotrexate

• Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis

  Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous injection for more

• UCB announces start of the EXXELERATE clinical study in rheumatoid arthritis

  UCB announced the start of the EXXELERATE™ study which will evaluate the short- and long-term efficacy of Cimzia® (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira®* (adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this stud more

• Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

  The use of genetic tests to predict a patient's response to drugs is increasingly important in the development of personalized medicine.  But genetic tests often only look for the most common gene variants.  In a pharmacogenomics study published in Genome Research, researchers have characterized rar more

Publications Methotrexate

• In vivo protection of activated Tyr22‐DHFR gene‐modified canine T lymphocytes from methotrexate

  ABSTRACT Background Nonmyeloablative allogeneic hematopoietic stem cell (HSC) transplantation can cure malignant and nonmalignant diseases affecting the hematopoietic system, such as severe combined immunodeficiencies, aplastic anemia and hemoglobinopathies. Although nonmyeloablative is favore more

• Pharmaceuticals, Vol. 6, Pages 579-603: Advances in Mammalian Cell Line Development Technologies for Recombinant Protein Production

  From 2006 to 2011, an average of 15 novel recombinant protein therapeutics have been approved by US Food and Drug Administration (FDA) annually. In addition, the expiration of blockbuster biologics has also spurred the emergence of biosimilars. The increasing numbers of innovator biologic products a more

• Resilient immortals, characterizing and utilizing Bax/Bak deficient Chinese hamster ovary (CHO) cells for high titer antibody production

  Cell death due to apoptosis is frequently observed in large‐scale manufacturing of therapeutic proteins, and can reduce product accumulation in bioreactors. Several different strategies that involve overexpression of antiapoptotic or downregulation of proapoptotic proteins have been designed in at more

Market studies Methotrexate

• Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

  Introduction Disease-modifying antirheumatic drugs (DMARDs) underpin the current management of rheumatoid arthritis. This will likely remain unchanged over the next decade. In spite of high costs, rheumatologists perceive there will be an increased penetration of biologic therapies in patients of a more

Websites Methotrexate